Five Prime Therapeutics, Inc.

Other

Bristol-myers Squibb Compnay

Glaxosmithkline Intellectual Property Development Limited

Ucbbiopharma Srl

Janine Powers

W Michael Kavanaugh

Thomas Brennan

Robert Sikorski

Robert Dean

Brian Wong

Katherine E Lewis

Kevin Hestir

Ernestine A Lee

David Bellovin

Emma Masteller

Julie Hambleton

Majid Ghoddusi

Servando Palencia

Kristen Pierce

Breda Twomey

Penny E Phillips

Michael Carleton

Kartik Sundareshwar Krishnan

Aaron Curtis Hinken

Amy W Hsu

Serena Kimi Perna

Ke Xu

Warren James Rocque

Dimple Pandya

Danielle E Kellar

Alan James Russell

Timothy Scott Johnson

The present invention relates to methods for the treatment of fibrosis. The invention discloses new research which demonstrates that interferon-lambda has directly acting anti-fibrotic effects both in vitro and in vivo and may be used to provide effective new therapies for the treatment of multiple types of fibrosis.

Medical use of interferon-lambda for the treatment of fibrosis

Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.

FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment

The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).

Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

Methods of treating muscle wasting and other disorders with NOPE extracellular domain (ECD) polypeptides and NOPE ECD fusion molecules are provided.

NOPE for treatment of pathological muscle loss and weakness

The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 3 (FGFR3) extracellular domain (ECD), including native FGFR3 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.

Hair growth methods using FGFR3 extracellular domains

The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 4 (FGFR4) extracellular domain (ECD), including native FGFR4 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.

Method of promoting hair growth using FGFR4 extracellular domains

Growing community of inventors

Alameda, CA, United States of America

Janine Powers